NK Cell-Based Immunotherapies in Cancer

키워드

참고문헌 (133)

1. Cheng M, "NK cell-based immunotherapy for malignant diseases", Cell Mol Immunol, 10, pp.230~252 (2013)
2. Morvan MG, "NK cells and cancer : you can teach innate cells new tricks", Nat Rev Cancer, 16, pp.7~19 (2016)
3. Long EO, "Controlling natural killer cell responses : integration of signals for activation and inhibition", Annu Rev Immunol, 31, pp.227~258 (2013)
4. Berry R, "Targeting of a natural killer cell receptor family by a viral immunoevasin", Nat Immunol, 14, pp.699~705 (2013)
5. Voskoboinik I, "Perforin-mediated target-cell death and immune homeostasis", Nat Rev Immunol, 6, pp.940~952 (2006)
6. Patel KR, "Multiple variables at the leukocyte cell surface impact fc gamma receptor-dependent mechanisms", Front Immunol, 10, pp.223~ (2019)
7. Karlhofer FM, "MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells", Nature, 358, pp.66~70 (1992)
8. Wagtmann N, "Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer", Immunity, 3, pp.801~809 (1995)
9. Bix M, "Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice", Nature, 349, pp.329~331 (1991)
10. Kärre K, "Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy", Nature, 319, pp.675~678 (1986)
11. Rodgers JR, "MHC class Ib molecules bridge innate and acquired immunity", Nat Rev Immunol, 5, pp.459~471 (2005)
12. Braud VM, "HLA-E binds to natural killer cell receptors CD94", NKG2A, B and C, 1998, pp.391, 795~799
13. Bashirova AA, "The killer immunoglobulin-like receptor gene cluster : tuning the genome for defense", Annu Rev Genomics Hum Genet, 7, pp.277~300 (2006)
14. Schenkel AR, "The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection", Front Immunol, 4, pp.90~ (2013)
15. Raulet DH, "Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors", Immunol Rev, 155, pp.41~52 (1997)
16. Lanier LL, "NK cell receptors", Annu Rev Immunol, 16, pp.359~393 (1998)
17. Yokoyama WM, "Immune functions encoded by the natural killer gene complex", Nat Rev Immunol, 3, pp.304~316 (2003)
18. Lee N, "HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences", J Immunol, 160, pp.4951~4960 (1998)
19. Forslund E, "Microchip-based single-cell imaging reveals that CD56dimCD57-KIR-NKG2A+ NK cells have more dynamic migration associated with increased target cell conjugation and probability of killing compared to CD56dimCD57-KIR-NKG2A-NK cells", J Immunol, 195, pp.3374~3381 (2015)
20. Viant C, "SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells", Nat Commun, 5, pp.5108~ (2014)
21. Mellman I, "Cancer immunotherapy comes of age", Nature, 480, pp.480~489 (2011)
22. Voena C, "Advances in cancer immunology and cancer immunotherapy", Discov Med, 21, pp.125~133 (2016)
23. Márquez-Rodas I, "Immune checkpoint inhibitors : therapeutic advances in melanoma", Ann Transl Med, 3, pp.267~ (2015)
24. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
25. Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
26. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
27. Melero I, "Therapeutic vaccines for cancer : an overview of clinical trials", Nat Rev Clin Oncol, 11, pp.509~524 (2014)
28. Kantoff PW, "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", N Engl J Med, 363, pp.411~422 (2010)
29. Yee C, "Endogenous T-cell therapy : clinical experience", Cancer J, 21, pp.492~500 (2015)
30. Maude SL, "Chimeric antigen receptor T cells for sustained remissions in leukemia", N Engl J Med, 371, pp.1507~1517 (2014)
31. Lamers CH, "Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells : clinical evaluation and management of on-target toxicity", Mol Ther, 21, pp.904~912 (2013)
32. Morgan RA, "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2", Mol Ther, 18, pp.843~851 (2010)
33. Sharma P, "Primary, adaptive, and acquired resistance to cancer immunotherapy", Cell, 168, pp.707~723 (2017)
34. Cheent K, "Natural killer cells : integrating diversity with function", Immunology, 126, pp.449~457 (2009)
35. Martín-Antonio B, "Natural killer cells : angels and devils for immunotherapy", Int J Mol Sci, 18, pp.18~ (2017)
36. Guillerey C, "Targeting natural killer cells in cancer immunotherapy", Nat Immunol, 17, pp.1025~1036 (2016)
37. Bradley M, "Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas-tumor cells", Blood, 92, pp.4248~4255 (1998)
38. Kayagaki N, "Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells", J Immunol, 163, pp.1906~1913 (1999)
39. Meyer-Monard S, "Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation", Transfusion, 49, pp.362~371 (2009)
40. Denman CJ, "Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells", PLoS One, 7, pp.e30264~ (2012)
41. Granzin M, "Shaping of natural killer cell antitumor activity by ex vivo cultivation", Front Immunol, 8, pp.458~ (2017)
42. Neelapu SS, "Chimeric antigen receptor T-cell therapy-assessment and management of toxicities", Nat Rev Clin Oncol, 15, pp.47~62 (2018)
43. Shah NN, "Mechanisms of resistance to CAR T cell therapy", Nat Rev Clin Oncol, 16, pp.372~385 (2019)
44. Schepisi G, "CAR-T cell therapy : a potential new strategy against prostate cancer", J Immunother Cancer, 7, pp.258~ (2019)
45. Parkhurst MR, "Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression", Clin Cancer Res, 17, pp.6287~6297 (2011)
46. Cantoni C, "NK cells, tumor cell transition, and tumor progression in solid malignancies : new hints for NK-based immunotherapy", J Immunol Res, 2016, pp.4684268~ (2016)
47. "ClinicalTrials.Gov"[URL]
48. Igarashi T, "Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells", Blood, 104, pp.170~177 (2004)
49. Terme M, "Natural killer cell-directed therapies : moving from unexpected results to successful strategies", Nat Immunol, 9, pp.486~494 (2008)
50. Ruggeri L, "Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation", Blood, 94, pp.333~339 (1999)
51. Ruggeri L, "Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants", Science, 295, pp.2097~2100 (2002)
52. Gill S, "Natural killer cells in allogeneic transplantation : effect on engraftment, graft-versus-tumor, and graft-versus-host responses", Biol Blood Marrow Transplant, 15, pp.765~776 (2009)
53. Ullah MA, "Functional reconstitution of natural killer cells in allogeneic hematopoietic stem cell transplantation", Front Immunol, 7, pp.144~ (2016)
54. Veluchamy JP, "The rise of allogeneic natural killer cells as a platform for cancer immunotherapy : recent innovations and future developments", Front Immunol, 8, pp.631~ (2017)
55. Spanholtz J, "Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process", PLoS One, 6, pp.e20740~ (2011)
56. Tonn T, "Treatment of patients with advanced cancer with the natural killer cell line NK-92", Cytotherapy, 15, pp.1563~1570 (2013)
57. Lim SA, "Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy", Cancer Res, 73, pp.2598~2607 (2013)
58. Wagner I, "Allele-level kir genotyping of more than a million samples : workflow, algorithm, and observations", Front Immunol, 9, pp.2843~ (2018)
59. Chambers AM, "Tumor microenvironment-induced immunometabolic reprogramming of natural killer cells", Front Immunol, 9, pp.2517~ (2018)
60. Habif G, "Targeting natural killer cells in solid tumors", Cell Mol Immunol, 16, pp.415~422 (2019)
61. Castagna L, "Re-discovering NK cell allo-reactivity in the therapy of solid tumors", J Immunother Cancer, 4, pp.54~ (2016)
62. Kornbluth J, "Cell surface phenotype of a cloned line of human natural killer cells", J Immunol, 129, pp.2831~2837 (1982)
63. Carotta S, "Targeting NK cells for anticancer immunotherapy : clinical and preclinical approaches", Front Immunol, 7, pp.152~ (2016)
64. Chabannon C, "Manufacturing natural killer cells as medicinal products", Front Immunol, 7, pp.504~ (2016)
65. Gong JH, "Characterization of a human cell line(NK-92)with phenotypical and functional characteristics of activated natural killer cells", Leukemia, 8, pp.652~658 (1994)
66. Hermanson DL, "Utilizing chimeric antigen receptors to direct natural killer cell activity", Front Immunol, 6, pp.195~ (2015)
67. Tam YK, "Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy", Hum Gene Ther, 10, pp.1359~1373 (1999)
68. Drexler HG, "Malignant hematopoietic cell lines : in vitro models for the study of natural killer cell leukemia-lymphoma", Leukemia, 14, pp.777~782 (2000)
69. Rezvani K, "Engineering natural killer cells for cancer immunotherapy", Mol Ther, 25, pp.1769~1781 (2017)
70. Tonn T, "Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92", J Hematother Stem Cell Res, 10, pp.535~544 (2001)
71. Klingemann H, "Natural killer cells for immunotherapy-Advantages of the NK-92 cell line over blood NK cells", Front Immunol, 7, pp.91~ (2016)
72. Yodoi J, "TCGF(IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line(YT cells)", J Immunol, 134, pp.1623~1630 (1985)
73. Harnack U, "Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells", Anticancer Res, 31, pp.475~479 (2011)
74. Tsuchiyama J, "Characterization of a novel human natural killer-cell line(NK-YS)established from natural killer cell lymphoma", leukemia associated with Epstein-Barr virus infection, 1998, pp.92, 1374~1383
75. Robertson MJ, "Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia", Exp Hematol, 24, pp.406~415 (1996)
76. Le Bouteiller P, "Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer(NK)cells to mediate cytotoxicity", Proc Natl Acad Sci U S A, 99, pp.16963~16968 (2002)
77. Chen X, "Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity", Proc Natl Acad Sci U S A, 104, pp.6329~6334 (2007)
78. Matsuo Y, "Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma", Leuk Res, 27, pp.935~945 (2003)
79. Mahle NH, "Kinetics of cellular cytotoxicity mediated by a cloned human natural killer cell line", Immunobiology, 179, pp.230~243 (1989)
80. Umehara H, "Involvement of protein tyrosine kinase p72syk and phosphatidylinositol 3-kinase in CD2-mediated granular exocytosis in the natural killer cell line, NK3. 3", J Immunol, 159, pp.1200~1207 (1997)
81. "EP3138905A1 EPO. Method for natural killer cell expansion"[URL]
82. "EP2539442A1 EPO. Method for the generation of a CIK cell and NK cell population"[URL]
83. "WO2017017184A1 WP. Modified natural killer cells and natural killer cell lines having increased cytotoxicity"[URL]
84. "tella, Inc. Press news: two patents related to NK cells, jointly applied with Kyushu University, was approved—successful manufacture of high performance NK cells (ZNK® cells) from a variety of cell sources"[URL]
85. Knorr DA, "Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy", Stem Cells Transl Med, 2, pp.274~283 (2013)
86. Woll PS, "Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity", J Immunol, 175, pp.5095~5103 (2005)
87. Woll PS, "Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity", Blood, 113, pp.6094~6101 (2009)
88. Eguizabal C, "Natural killer cells for cancer immunotherapy : pluripotent stem cells-derived NK cells as an immunotherapeutic perspective", Front Immunol, 5, pp.439~ (2014)
89. Hermanson DL, "Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer", Stem Cells, 34, pp.93~101 (2016)
90. Bernareggi D, "Development of innate immune cells from human pluripotent stem cells", Exp Hematol, 71, pp.13~23 (2019)
91. Carlsten M, "Genetic manipulation of NK cells for cancer immunotherapy : TECHNIQUES and clinical implications", Front Immunol, 6, pp.266~ (2015)
92. Zeng J, "Generation of"off-the-shelf"natural killer cells from peripheral blood cell-derived induced pluripotent stem cells", Stem Cell Reports, 9, pp.1796~1812 (2017)
93. Rezvani K, "The application of natural killer cell immunotherapy for the treatment of cancer", Front Immunol, 6, pp.578~ (2015)
94. Giudice A, "Genetic modification of human embryonic stem cells for derivation of target cells", Cell Stem Cell, 2, pp.422~433 (2008)
95. Xie F, "Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR", Cas9 and piggyBac, 2014, pp.24, 1526~1533
96. Knorr DA, "Pluripotent stem cell-derived natural killer cells for cancer therapy", Transl Res, 156, pp.147~154 (2010)
97. Martin CH, "Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells", Blood, 112, pp.2730~2737 (2008)
98. Li Y, "Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity", Cell Stem Cell, 23, pp.181~192 (2018)
99. Crow D, "Could iPSCs enable"off-the-shelf"cell therapy", Cell, 177, pp.1667~1669 (2019)
100. "First-ever CAR T-cell therapy approved in U.S", Cancer Discov, 7, pp.OF1~ (2017)
101. "FDA approves second CAR T-cell therapy", Cancer Discov, 8, pp.5~6 (2018)
102. Stirrups R, "CAR T-cell therapy in refractory large B-cell lymphoma", Lancet Oncol, 19, pp.e19~ (2018)
103. Fan M, "Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia", J Hematol Oncol, 10, pp.151~ (2017)
104. Jensen MC, "Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells", Immunol Rev, 257, pp.127~144 (2014)
105. Wang J, "Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains", Hum Gene Ther, 18, pp.712~725 (2007)
106. Chmielewski M, "TRUCKs : the fourth generation of CARs", Expert Opin Biol Ther, 15, pp.1145~1154 (2015)
107. Chmielewski M, "IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression", Cancer Res, 71, pp.5697~5706 (2011)
108. Gilfillan S, "NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation", Nat Immunol, 3, pp.1150~1155 (2002)
109. Trinchieri G, "The choices of a natural killer", Nat Immunol, 4, pp.509~510 (2003)
110. Chang YH, "A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells", Cancer Res, 73, pp.1777~1786 (2013)
111. McNerney ME, "2B4(CD244)is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells", Mol Immunol, 42, pp.489~494 (2005)
112. Altvater B, "2B4(CD244)signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells", Clin Cancer Res, 15, pp.4857~4866 (2009)
113. Zhang C, "Chimeric antigen receptor-engineered nk-92 cells : an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity", Front Immunol, 8, pp.533~ (2017)
114. Kloess S, "CAR-expressing natural killer cells for cancer retargeting", Transfus Med Hemother, 46, pp.4~13 (2019)
115. Rizvi NA, "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer(CheckMate 063) : a phase 2, single-arm trial", Lancet Oncol, 16, pp.257~265 (2015)
116. Robert C, "Nivolumab in previously untreated melanoma without BRAF mutation", N Engl J Med, 372, pp.320~330 (2015)
117. Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma", N Engl J Med, 372, pp.2521~2532 (2015)
118. Zhou G, "Towards curative cancer immunotherapy : overcoming posttherapy tumor escape", Clin Dev Immunol, 2012, pp.124187~ (2012)
119. Balar AV, "First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer(KEYNOTE-052) : a multicentre, single-arm, phase 2 study", Lancet Oncol, 18, pp.1483~1492 (2017)
120. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
121. Kanjanapan Y, "Hyperprogressive disease in early-phase immunotherapy trials : clinical predictors and association with immune-related toxicities", Cancer, 125, pp.1341~1349 (2019)
122. Piñeiro Fernández J, "Hepatic tumor microenvironments and effects on NK cell phenotype and function", Int J Mol Sci, 20, pp.20~ (2019)
123. Gonzalez-Gugel E, "Modulation of innate immunity in the tumor microenvironment", Cancer Immunol Immunother, 65, pp.1261~1268 (2016)
124. Hasmim M, "Critical role of tumor microenvironment in shaping NK cell functions : implication of hypoxic stress", Front Immunol, 6, pp.482~ (2015)
125. Parodi M, "Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration", Front Immunol, 9, pp.2358~ (2018)
126. Laconi E, "The evolving concept of tumor microenvironments", BioEssays, 29, pp.738~744 (2007)
127. Noman MZ, "Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response", Crit Rev Immunol, 31, pp.357~377 (2011)
128. Gassmann M, "Regulation of the hypoxia-inducible factor-1 alpha. ARNT is not necessary for hypoxic induction of HIF-1 alpha in the nucleus", Adv Exp Med Biol, 475, pp.87~99 (2000)
129. Sarkar S, "Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells", PLoS One, 8, pp.e64835~ (2013)
130. Dengler VL, "Transcriptional regulation by hypoxia inducible factors", Crit Rev Biochem Mol Biol, 49, pp.1~15 (2014)
131. Albini A, "Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment : implications for immunotherapy", Front Immunol, 9, pp.527~ (2018)
132. Furuta E, "Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1", Cancer Res, 68, pp.1003~1011 (2008)
133. Gillies RJ, "Causes and consequences of increased glucose metabolism of cancers", J Nucl Med, 49(Suppl 2), pp.24S~42S (2008)

관련 논문AI추천